First Mediterranean Thematic Workshop on Advanced Molecular Brain Imaging with Compact High Performance MRI-Compatible PET and SPECT Imagers – Potential for a Paradigm Shift

Session

Neurodegenerative diseases and clinical need for Imaging

1 Sept 2012, 13:30

Giardini di Naxos (Taormina, Sicily)

9. FDG and Amyloid imaging in Alzheimer's disease

Dr A. Chiaravalloti

01/09/2012, 13:30

Abstract. The pathophysiological hallmark of Alzheimer’s disease (AD) is the accumulation of amyloid plaques in the brain with a fairly constant distribution pattern involving the basal portions of the frontal, temporal and occipital lobe with a partial saving of the hippocampal formation and primary sensory areas[1]. In vivo 2-deoxy-2-(18F) fluoro-D-glucose (18F-FDG) PET is a minimally...

10. Molecular Imaging of Parkinson disease

Dr A. Varrone

01/09/2012, 14:05

Abstract. The development of radioligands for the dopaminergic system has provided suitable imaging biomarkers for clinical research in Parkinson´s disease and related movement disorders. Single photon emission tomography (SPECT) has played an important role as main molecular imaging modality because of the availability of imaging tools such as dopamine transporter (DAT) radioligands for wide...

11. Neurodegeneration markers from structural MRI and FDG-PET brain images: the Alzheimer’s disease case study

Dr A. Chincarini

01/09/2012, 14:40

In the framework of neurodegenerative diseases, and in particular the Alzheimer's disease (AD), we are witnessing an increasing presence of neuroimaging data, magnetic resonant images (MRI) and positron emission tomography (PET) above all. Despite the fact that clinical scanners have been around for some decades, MRI and PET images have only recently become a dependable support in diagnosing...